Cell cycle gene networks are associated with melanoma prognosis

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Wang, Li ^a   Hurley, Daniel G ^a,b   Watkins, Wendy ^a   Araki, Hiromitsu ^a,d   Tamada, Yoshinori ^c,d   Muthukaruppan, Anita ^a   Ranjard, Louis ^a   Derkac, Eliane ^a   Imoto, Seiya ^c   Miyano, Satoru ^c   Crampin, Edmund J ^a,b   Print, Cristin G ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF TOKYO   (Japan)

^d GNI Ltd   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

RNA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR;

APOPTOSIS; ARTICLE; BAYES THEOREM; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; FUNCTIONAL GENOMICS; GENE CLUSTER; GENE REGULATORY NETWORK; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNE RESPONSE; IN VITRO STUDY; MELANOMA; MELANOMA CELL; MICROARRAY ANALYSIS; MOLECULAR CLONING; PROGNOSIS; BIOLOGICAL MODEL; CLUSTER ANALYSIS; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC TRANSCRIPTION; GENETICS; META ANALYSIS (TOPIC); METABOLISM; METASTASIS; NONPARAMETRIC TEST; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RNA INTERFERENCE; SKIN TUMOR; TUMOR CELL LINE;

BAYES THEOREM; CELL CYCLE; CELL LINE, TUMOR; CLUSTER ANALYSIS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GENE REGULATORY NETWORKS; HUMANS; MELANOMA; META-ANALYSIS AS TOPIC; MODELS, GENETIC; NEOPLASM METASTASIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RNA INTERFERENCE; SKIN NEOPLASMS; STATISTICS, NONPARAMETRIC; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 84859940344     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034247     Document Type: Article

References (83)

1. New Zealand Ministry of Health (2010) Cancer: New Registrations and Deaths 2006. Wellington Ministry of Health PO Box 5013, Wellington, New Zealand.
2. Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, et al. (2004) Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 22: 1118-1125.
3. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, et al. (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467: 596-599.
4. Ribas A, Camacho LH, Lee SM, Hersh EM, Brown CK, et al. (2010) Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma. J Transl Med 8: 89.
5. Berd D, Sato T, Maguire HC Jr, Kairys J, Mastrangelo MJ, (2004) Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol 22: 403-415.
6. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-723.
7. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, et al. (2010) Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28: 3167-3175.
8. Chowdhery R, Gonzalez R, (2011) Immunologic therapy targeting metastatic melanoma: allovectin-7. Immunotherapy 3: 17-21.
9. Goldstein AM, Chan M, Harland M, Hayward NK, Demenais F, et al. (2007) Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet 44: 99-106.
10. Goldstein AM, Struewing JP, Chidambaram A, Fraser MC, Tucker MA, (2000) Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations. J Natl Cancer Inst 92: 1006-1010.
11. Bataille V, Hiles R, Bishop JA, (1995) Retinoblastoma, melanoma and the atypical mole syndrome. Br J Dermatol 132: 134-138.
12. Firoz EF, Warycha M, Zakrzewski J, Pollens D, Wang G, et al. (2009) Association of MDM2 SNP309, age of onset, and gender in cutaneous melanoma. Clin Cancer Res 15: 2573-2580.
13. Meyle KD, Guldberg P, (2009) Genetic risk factors for melanoma. Hum Genet 126: 499-510.
14. Dai DL, Martinka M, Li G, (2005) Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J Clin Oncol 23: 1473-1482.
15. Wu H, Goel V, Haluska FG, (2003) PTEN signaling pathways in melanoma. Oncogene 22: 3113-3122.
16. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, et al. (1998) Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95: 29-39.
17. van Elsas A, Zerp SF, van der Flier S, Kruse KM, Aarnoudse C, et al. (1996) Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am J Pathol 149: 883-893.
18. Dong J, Phelps RG, Qiao R, Yao S, Benard O, et al. (2003) BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res 63: 3883-3885.
19. Dhomen N, Marais R, (2009) BRAF signaling and targeted therapies in melanoma. Hematol Oncol Clin North Am 23: 529-545, ix.
20. Akslen LA, Angelini S, Straume O, Bachmann IM, Molven A, et al. (2005) BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. J Invest Dermatol 125: 312-317.
21. Lopez-Bergami P, Huang C, Goydos JS, Yip D, Bar-Eli M, et al. (2007) Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell 11: 447-460.
22. Carreira S, Goodall J, Aksan I, La Rocca SA, Galibert MD, et al. (2005) Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. Nature 433: 764-769.
23. Du J, Widlund HR, Horstmann MA, Ramaswamy S, Ross K, et al. (2004) Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell 6: 565-576.
24. Bilican B, Goding CR, (2006) Cell cycle regulation of the T-box transcription factor tbx2. Exp Cell Res 312: 2358-2366.
25. Bondurand N, Pingault V, Goerich DE, Lemort N, Sock E, et al. (2000) Interaction among SOX10, PAX3 and MITF, three genes altered in Waardenburg syndrome. Hum Mol Genet 9: 1907-1917.
26. Goodall J, Carreira S, Denat L, Kobi D, Davidson I, et al. (2008) Brn-2 represses microphthalmia-associated transcription factor expression and marks a distinct subpopulation of microphthalmia-associated transcription factor-negative melanoma cells. Cancer Res 68: 7788-7794.
27. Salti GI, Manougian T, Farolan M, Shilkaitis A, Majumdar D, et al. (2000) Micropthalmia transcription factor: a new prognostic marker in intermediate-thickness cutaneous malignant melanoma. Cancer Res 60: 5012-5016.
28. Hoek KS, Schlegel NC, Brafford P, Sucker A, Ugurel S, et al. (2006) Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res 19: 290-302.
29. Cheli Y, Giuliano S, Botton T, Rocchi S, Hofman V, et al. (2011) Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny. Oncogene 30: 2307-2318.
30. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, et al. (2005) Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436: 117-122.
31. Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, et al. (2000) Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406: 536-540.
32. Hoek KS, (2009) Melanoma progression, gene expression and DNA microarrays. G Ital Dermatol Venereol 144: 39-49.
33. Kunz M, (2008) DNA microarray technology in dermatology. Semin Cutan Med Surg 27: 16-24.
34. Nambiar S, Mirmohammadsadegh A, Hengge UR, (2008) Cutaneous melanoma: fishing with chips. Curr Mol Med 8: 235-243.
35. Ren S, Liu S, Howell P Jr, Xi Y, Enkemann SA, et al. (2008) The impact of genomics in understanding human melanoma progression and metastasis. Cancer Control 15: 202-215.
36. Gajewski TF, Louahed J, Brichard VG, (2010) Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J 16: 399-403.
37. Hatanaka Y, Nagasaki M, Yamaguchi R, Obayashi T, Numata K, et al. (2008) A novel strategy to search conserved transcription factor binding sites among coexpressing genes in human. Genome Inform 20: 212-221.
38. Obayashi T, Kinoshita K, (2009) Rank of correlation coefficient as a comparable measure for biological significance of gene coexpression. DNA Res 16: 249-260.
39. Stuart JM, Segal E, Koller D, Kim SK, (2003) A gene-coexpression network for global discovery of conserved genetic modules. Science 302: 249-255.
40. Obayashi T, Kinoshita K, (2011) COXPRESdb: a database to compare gene coexpression in seven model animals. Nucleic Acids Res 39: D1016-1022.
41. Viswanathan GA, Seto J, Patil S, Nudelman G, Sealfon SC, (2008) Getting started in biological pathway construction and analysis. PLoS Comput Biol 4: e16.
42. Song S, Black MA, (2008) Microarray-based gene set analysis: a comparison of current methods. BMC Bioinformatics 9: 502.
43. Hoek K, Rimm DL, Williams KR, Zhao H, Ariyan S, et al. (2004) Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res 64: 5270-5282.
44. Bansal M, Belcastro V, Ambesi-Impiombato A, di Bernardo D, (2007) How to infer gene networks from expression profiles. Mol Syst Biol 3: 78.
45. Butte AJ, Tamayo P, Slonim D, Golub TR, Kohane IS, (2000) Discovering functional relationships between RNA expression and chemotherapeutic susceptibility using relevance networks. Proc Natl Acad Sci U S A 97: 12182-12186.
46. Imoto S, Tamada Y, Araki H, Yasuda K, Print C, et al. (2006) Computational strategy for discovering druggable gene networks from genome-wide RNA expression profiles. Pacific Symposium on Biocomputing 11: 559-571.
47. Tamada Y, Imoto S, Araki H, Nagasaki M, Print C, et al. (2011) Estimating Genome-wide Gene Networks Using Nonparametric Bayesian Network Models on Massively Parallel Computers. IEEE/ACM Trans Comput Biol Bioinform 8: 683-697.
48. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I, (2001) Controlling the false discovery rate in behavior genetics research. Behav Brain Res 125: 279-284.
49. Chang JT, Nevins JR, (2006) GATHER: a systems approach to interpreting genomic signatures. Bioinformatics 22: 2926-2933.
50. Matys V, Fricke E, Geffers R, Gossling E, Haubrock M, et al. (2003) TRANSFAC: transcriptional regulation, from patterns to profiles. Nucleic Acids Res 31: 374-378.
51. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, et al. (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25: 25-29.
52. Kanehisa M, Goto S, Furumichi M, Tanabe M, Hirakawa M, (2010) KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res 38: D355-360.
53. Lee HK, Hsu AK, Sajdak J, Qin J, Pavlidis P, (2004) Coexpression analysis of human genes across many microarray data sets. Genome Res 14: 1085-1094.
54. Jaeger J, Koczan D, Thiesen HJ, Ibrahim SM, Gross G, et al. (2007) Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. Clin Cancer Res 13: 806-815.
55. Riker AI, Enkemann SA, Fodstad O, Liu S, Ren S, et al. (2008) The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics 1: 13.
56. Xu L, Shen SS, Hoshida Y, Subramanian A, Ross K, et al. (2008) Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases. Mol Cancer Res 6: 760-769.
57. Bogunovic D, O'Neill DW, Belitskaya-Levy I, Vacic V, Yu YL, et al. (2009) Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci U S A 106: 20429-20434.
58. Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, et al. (2006) Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst 98: 472-482.
59. Tibshirani R, Hastie T, Narasimhan B, Chu G, (2002) Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 99: 6567-6572.
60. Jung CR, Hwang KS, Yoo J, Cho WK, Kim JM, et al. (2006) E2-EPF UCP targets pVHL for degradation and associates with tumor growth and metastasis. Nat Med 12: 809-816.
61. Timar J, Gyorffy B, Raso E, (2010) Gene signature of the metastatic potential of cutaneous melanoma: too much for too little? Clin Exp Metastasis 27: 371-387.
62. Bild AH, Yao G, Chang JT, Wang Q, Potti A, et al. (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439: 353-357.
63. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, et al. (2006) The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313: 1929-1935.
64. Ch'ng S, Tan ST, (2009) Genetics, cellular biology and tumor microenvironment of melanoma. Front Biosci 14: 918-928.
65. Neagu M, Constantin C, Tanase C, (2010) Immune-related biomarkers for diagnosis/prognosis and therapy monitoring of cutaneous melanoma. Expert Rev Mol Diagn 10: 897-919.
66. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, et al. (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27: 6199-6206.
67. Ryan RF, Krementz ET, Litwin MS, (1988) A role for topical 5-fluorouracil therapy in melanoma. J Surg Oncol 38: 250-256.
68. Okoniewski MJ, Miller CJ, (2006) Hybridization interactions between probesets in short oligo microarrays lead to spurious correlations. BMC Bioinformatics 7: 276.
69. Klebanov L, Chen L, Yakovlev A, (2007) Revisiting adverse effects of cross-hybridization in Affymetrix gene expression data: do they matter for correlation analysis? Biol Direct 2: 28.
70. Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, et al. (1973) In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 51: 1417-1423.
71. Halaban R, Krauthammer M, Pelizzola M, Cheng E, Kovacs D, et al. (2009) Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications. PLoS One 4: e4563.
72. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, et al. (2003) Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31: e15.
73. Parman C, Halling C, (2006) affyQCReport: A Package to Generate QC Reports for Affymetrix Array Data.
74. Smyth GK, (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article3.
75. Marot G, Foulley JL, Mayer CD, Jaffrezic F, (2009) Moderated effect size and P-value combinations for microarray meta-analyses. Bioinformatics 25: 2692-2699.
76. Kanehisa M, Goto S, Hattori M, Aoki-Kinoshita KF, Itoh M, et al. (2006) From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res 34: D354-357.
77. Kaufman L, Rousseeuw PJ, (1990) Finding Groups in Data: An Introduction to Cluster Analysis. New York WIley.
78. Mandruzzato S, Callegaro A, Turcatel G, Francescato S, Montesco MC, et al. (2006) A gene expression signature associated with survival in metastatic melanoma. J Transl Med 4: 50.
79. John T, Black MA, Toro TT, Leader D, Gedye CA, et al. (2008) Predicting clinical outcome through molecular profiling in stage III melanoma. Clin Cancer Res 14: 5173-5180.
80. Smith AP, Hoek K, Becker D, (2005) Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/melanoma in situ and advanced-stage melanomas. Cancer Biol Ther 4: 1018-1029.
81. Talantov D, Mazumder A, Yu JX, Briggs T, Jiang Y, et al. (2005) Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res 11: 7234-7242.
82. Jeffs AR, Glover AC, Slobbe LJ, Wang L, He S, et al. (2009) A gene expression signature of invasive potential in metastatic melanoma cells. PLoS One 4: e8461.
83. Haqq C, Nosrati M, Sudilovsky D, Crothers J, Khodabakhsh D, et al. (2005) The gene expression signatures of melanoma progression. Proc Natl Acad Sci U S A 102: 6092-6097.